La taille du marché des agents emboliques liquides périphériques devrait atteindre 81,41 millions de dollars US d’ici 2031, contre 40,42 millions de dollars US en 2023. Le marché devrait enregistrer un TCAC de 9,1 % au cours de la période 2023-2031. L’intérêt croissant et les développements dans les systèmes à changement de phase induits par la température et les agents emboliques déclenchés par le pH sont susceptibles d’apporter de nouvelles tendances sur le marché des agents emboliques liquides périphériques.
Analyse du marché des agents emboliques liquides périphériques
Les agents emboliques liquides sont principalement utilisés dans des procédures mini-invasives, telles que l'embolisation, pour traiter les anévrismes, les malformations artério-veineuses, les tumeurs et d'autres affections. Ces agents offrent une alternative moins invasive aux méthodes chirurgicales traditionnelles et permettent aux médecins un plus grand contrôle et une plus grande précision dans la fermeture des vaisseaux sanguins tout en minimisant le traumatisme du patient et les temps de récupération. Les innovations technologiques devraient améliorer les performances des produits et favoriser une adoption plus large dans diverses applications en aval. En outre, le marché des agents emboliques liquides périphériques est en croissance en raison de leur adoption et de leur acceptation croissantes par les patients et les professionnels de la santé en raison de la prise de conscience croissante des avantages apportés par les agents emboliques liquides dans le traitement des maladies vasculaires périphériques.
Aperçu du marché des agents emboliques liquides périphériques
Les agents emboliques liquides sont utilisés pour traiter les maladies vasculaires périphériques telles que la varicocèle et l'embolisation des artères périphériques. Le marché de ces agents est stimulé par la préférence croissante des patients et des professionnels de santé pour les procédures mini-invasives. L’introduction des dernières technologies médicales, telles que les agents emboliques liquides, soutenue par l’augmentation des dépenses de santé à l’échelle mondiale et l’amélioration des infrastructures de santé dans les marchés émergents, stimule l’expansion du marché des agents emboliques liquides périphériques. En outre, les pratiques de remboursement favorables pour les procédures mini-invasives utilisant des agents emboliques liquides dans de nombreux pays favorisent leur acceptation et stimulent l’expansion du marché.
Personnalisez la recherche en fonction de vos besoins
Nous pouvons optimiser et adapter l’analyse et la portée qui ne sont pas satisfaites par nos offres standard. Cette flexibilité vous aidera à obtenir les informations exactes nécessaires à la planification de votre entreprise et à la prise de décision.
Marché des agents emboliques liquides périphériques : perspectives stratégiques
TCAC (2023 - 2031)9,1%- Taille du marché 2023
40,42 millions de dollars américains - Taille du marché 2031
81,41 millions de dollars américains
Dynamique du marché
- La prévalence croissante des otites contribue à la croissance du marché
- Initiatives stratégiques des entreprises pour promouvoir la croissance du marché
- La prise de conscience croissante de la santé de l’oreille favorise la croissance du marché
Joueurs clés
- Olympe Amérique,
- Medtronic,
- Sommet Médical,
- GRÂCE MÉDICALE,
- Préceptis Médical,
- Atos Médical,
- Medasil Surgical Ltd,
- Adepte Médical Limité,
- Smith et neveu Plc,
- Sciences de la vie Integra,
Aperçu régional
- Amérique du Nord
- L'Europe
- Asie-Pacifique
- Amérique du Sud et Centrale
- Moyen-Orient et Afrique
Segmentation du marché
Produit- Applicateurs/Inserteurs de tubes
- Tubes de tympanostomie
Matériel- Silicone
- Fluoroplastique
- Titane
- Acier inoxydable
Application- Otite moyenne aiguë
- Otite moyenne récurrente avec épanchement
Utilisateur final- Hôpitaux
- Centres chirurgicaux ambulatoires
- Cliniques spécialisées
- L'exemple de PDF présente la structure du contenu et la nature des informations avec une analyse qualitative et quantitative.
Moteurs et opportunités du marché des agents emboliques liquides périphériques
Incidence croissante des maladies vasculaires périphériques
Peripheral vascular disease (PVD) consists of peripheral arterial disease (PAD) and venous disease. The growing prevalence of PVD can be attributed to the proliferating aging population that increases the visibility of its various diagnostic and treatment modalities. According to the article “Income-Related Peripheral Artery Disease Treatment,” published in the National Library of Medicine, more than 200 million people across the world suffer from PAD, and ~10% of people aged 50 years and above have been affected by the disease in Western Europe and North America. The prevalence of PVD ranges from 3% in patients aged >55 years and 11% in patients aged >65 years to 20% in patients aged >75. According to a study published in the National Library of Medicine titled "Secular Trends in the Epidemiological Patterns of Peripheral Artery Disease and Risk Factors in China," the number of people suffering from peripheral arterial disease in China increased by 40% between 2000 and 2020. In 2020, ~41 million adults in China were affected by PAD. In 2020, epidemiological research in China also found that the prevalence of PAD in the general population aged 35 years and above was 6%, and the prevalence of PAD in elderly over 60 years of age was 15% in China. It is estimated that there are more than 30 million patients suffering from peripheral artery disease in the country.
The rising prevalence of PVD is attributed to the increasing risk factors associated with diabetes, smoking, obesity, and age. With unhealthy lifestyle changes and the availability of medications not enough to treat PVD symptoms, minimally invasive procedures using peripheral stents are often the standard treatment. Cerebrovascular/carotid disease, peripheral arterial disease, and abdominal aortic aneurysms are among the most common peripheral vasculopathies reported by primary care physicians. All require aggressive medical treatment to prevent potentially serious complications and require vascular surgeons for evaluation. Liquid embolic agents are usually injected and introduced into the vascular malformation sites using a catheter guided by X-ray imaging (i.e., angiography). After infusion of the liquid embolic agents, it changes into a solid implant in situ, based on different mechanisms, including precipitation, polymerization, and cross-linking, through ionic or thermal processes. Liquid embolic agents do not rely on the patient's coagulation system for complete occlusion and may be effective even in patients suffering from severe coagulopathy. If a catheter cannot reach a bleeding site, liquid agents can provide embolization distal to the catheter tip. Long-term treatment strategies, better outcomes, and regulations to reduce cardiovascular mortality are recommended by all major regions, comprising the European Society of Cardiology (ESC), the European Society for Vascular Surgery (ESVS), the American Heart Association (AHA), and American College of Cardiology (ACC). Therefore, the growing prevalence of PVD drives the peripheral liquid embolic agents market growth.
Growing Strategic Initiatives by Market Players
Market players are constantly focusing on maintaining their leadership position in the market by continuously working toward strategic initiatives, introducing new products, and improving the existing products to broaden the usage of peripheral liquid embolic agents.
- In November 2023, Fluidx Medical Technology announced the development of its ultra-peripheral embolism platform for bleeding, tumor treatment, and other proximal embolization applications. The press release states that the ultra platform is designed to make catheter-based therapeutic embolization procedures safer, better, and faster.
- In October 2023, Sirtex Medical announced the commercial availability of the LAVA - Liquid Embolic System, a liquid embolic agent approved for treating peripheral vascular bleeding. LAVA offers volume and viscosity options that optimize flexibility in treating patients with controlled target vessel occlusion. The product's 2 mL and 6 mL options are optimized for the peripheral vasculature, and its viscosity options enable distal embolization of small vessels that may not be accessible via other emboli.
- In May 2023, Grand Pharmaceutical Group Ltd. acquired an 87.5% stake in Blackswan Vascular Inc., a company developing liquid embolism for peripheral vascular applications. The company continues to expand its presence in tumor intervention.
Thus, new product launches based on advancements and strategic initiatives are likely to provide new opportunities for the peripheral liquid embolic agents market in the coming years.
Peripheral Liquid Embolic Agents Market Report Segmentation Analysis
Key segments that contributed to the derivation of the peripheral liquid embolic agents market analysis are type and application.
- By type, the peripheral liquid embolic agents market is bifurcated into polymerizing liquid embolic agents and precipitating liquid embolic agents. In 2023, the precipitating liquid embolic agents segment held a larger market share and is anticipated to register a higher CAGR during 2023–2031.
- In terms of application, the market is segmented into endoleak type II, malformations, bleedings and trauma, varicose vein, tumors, and visceral aneurysm. In 2023, the endoleak type II segment held the largest share of the market. However, the bleedings and trauma segment is estimated to register the highest CAGR from 2023 to 2031.
Peripheral Liquid Embolic Agents Market Share Analysis by Geography
The geographic scope of the peripheral liquid embolic agents market report is mainly divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America.
North America holds the largest share of the peripheral liquid embolic agents market. The regional market growth is propelled by the increasing incidence of vascular diseases, growing strategic initiatives by the market players, supportive government plans, and the development of innovative liquid embolic products. Canada held the largest share of the peripheral liquid embolic agents market in North America in 2023. The market is expected to grow owing to the availability of advanced healthcare infrastructure and rising incidence of target conditions. However, Asia Pacific is expected to register the highest CAGR during 2023–2031. The Asia Pacific market growth is driven by various factors such as the rising prevalence of peripheral artery diseases (PAD), increasing demand for minimally invasive procedures, growing number of hospitals and ambulatory surgery centers, market players are focusing on developing countries for growth opportunities, and developing healthcare infrastructure in Asia Pacific. In the region, China held the largest market share in 2023 as the market players in China are engaged in strategic activities to expand their footprint in the market. In May 2021, Grand Pharmaceutical and Healthcare Holdings Limited acquired Shenming Medical Technology Co., Ltd. The company obtained all rights of an innovative thermosensitive embolic agent that is used for liver cancer treatment, further expanding the tumor intervention treatment product pipeline.
Peripheral Liquid Embolic Agents Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 40.42 Million |
| Market Size by 2031 | US$ 81.41 Million |
| Global CAGR (2023 - 2031) | 9.1% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered | By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Peripheral Liquid Embolic Agents Market News and Recent Developments
Le marché des agents emboliques liquides périphériques est évalué en collectant des données qualitatives et quantitatives après des recherches primaires et secondaires, qui comprennent d’importantes publications d’entreprise, des données d’association et des bases de données. Quelques-uns des développements sur le marché des agents emboliques liquides périphériques sont répertoriés ci-dessous :
- CERENOVUS Inc., a lancé l'ensemble de procédures du système embolique liquide TRUFILL n-BCA. Le dernier ajout à la gamme d'AVC hémorragique de CERENOVUS propose le système embolique liquide TRUFILL n-BCA sous la forme d'un nouvel ensemble procédural qui comprend deux configurations et les accessoires nécessaires pour préparer et administrer le système embolique liquide n-BCA dans un ensemble stérilisé, créant ainsi une préparation de procédure rationalisée. (Source : Johnson & Johnson, communiqué de presse, mars 2024)
- Sirtex Medical (« Sirtex ») a lancé un produit unique en son genre pour traiter l'hémorragie vasculaire périphérique. LAVA offre des options de volume et de viscosité qui optimisent la flexibilité pour traiter les patients affectés par une occlusion contrôlée du vaisseau cible. La capacité du produit à maximiser la densité de tassement dans le vaisseau cible est extrêmement importante, car elle permet de minimiser la probabilité d'une récidive future ou d'un rétablissement de la perméabilité du vaisseau. (Source : Sirtex Medical, communiqué de presse, octobre 2023)
- Balt a ouvert un deuxième bureau en France. Le bureau parisien accueillerait les membres des équipes commerciales, marketing, affaires cliniques, financières, informatiques, juridiques, RH et communication. (Source : Balt, communiqué de presse, juin 2022)
Couverture et livrables du rapport sur le marché des agents emboliques liquides périphériques
Le rapport « Taille et prévisions du marché des agents emboliques liquides périphériques (2021-2031) » fournit une analyse détaillée du marché couvrant les domaines suivants :
- Taille et prévisions du marché des agents emboliques liquides périphériques aux niveaux mondial, régional et national pour tous les segments de marché clés couverts par le champ d’application.
- Tendances du marché des agents emboliques liquides périphériques ainsi que dynamiques du marché telles que les moteurs, les contraintes et les opportunités clés
- Analyse PEST et SWOT détaillée
- Analyse du marché des agents emboliques liquides périphériques couvrant les principales tendances du marché, le cadre mondial et régional, les principaux acteurs, les réglementations et les développements récents du marché
- Analyse du paysage industriel et de la concurrence couvrant la concentration du marché, l’analyse de la carte thermique, les principaux acteurs et les développements récents du marché des agents emboliques liquides périphériques
- Profils d'entreprises détaillés
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market is estimated to reach US$ 81.41 million by 2031.
North America dominated the market in 2023.
The rising incidence of peripheral vascular diseases and upsurging demand for minimally invasive procedures are among the factors driving the market.
Medtronic, Gem Srl, MicroVention Inc, Johnson and Johnson, and Balt are among the leading players operating in the market.
The growing focus and developments in temperature-induced phase change systems and pH-triggered embolic agents are likely to bring new trends in the market.
The market is expected to register a CAGR of 9.1% during 2023–2031.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Peripheral Liquid Embolic Agents Market
- Medtronic
- B Braun SE
- Guerbet SA
- Sirtex Medical Ltd
- Balt
- MicroVention Inc
- Johnson & Johnson
- GEM srl
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For